Opzelura

(ruxolitinib)
Opzeulura 1.5 % Topical Cream

Dosage & administration

drug label

Opzelura prescribing information

prior authorization

Opzelura prior authorization resources

Most recent Opzelura prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Mar 02, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Mar 02, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Mar 02, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form
Verified: Mar 02, 2024Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Complete Letter of Medical Necessity
Coverage Authorization Appeal
Letter of Appeal - Additional Tube of Opzelura
Learn More

Benefits investigation

Prescription & PAP Enrollment Form
Learn More

financial assistance

Opzelura financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program: Atopic Dermatitis
Activate Copay Savings Card (If already have one)
Enroll in Patient Savings Program: Nonsegmental Vitiligo
Learn More

Bridge program

commercial only
Prescription & Commercial Access Enrollment Form - Bridge Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Prescription & PAP Enrollment Form
Learn More

PubMed™ | Opzelura

Opzelura PubMed™ News

patient education

Opzelura patient education

Getting started on Opzelura

Instructions For Use: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Instructions For Use: Nonsegmental Vitiligo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Opzelura: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure (Spanish): Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Treatment Tracker: Atopic Dermatitis
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Nonsegmental Vitiligo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Opzelura: Nonsegmental Vitiligo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Treatment Journal: Nonsegmental Vitiligo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Treatment Tracker: Nonsegmental Vitiligo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

Other resources

App Download: Nonsegmental Vitiligo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Opzelura FAQs

Is there a pregnancy exposure registry for OPZELURA?Yes, there is a pregnancy registry that monitors pregnancy outcomes in pregnant persons exposed to OPZELURA during pregnancy. Pregnant persons exposed to OPZELURA and healthcare providers should report OPZELURA exposure by calling 1-855-463-3463.
What is the risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes with OPZELURA?Available data from pregnancies reported in clinical trials with OPZELURA are not sufficient to evaluate a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, oral administration of ruxolitinib to pregnant rats and rabbits during the period of organogenesis resulted in adverse developmental outcomes at doses associated with maternal toxicity. The background risks of major birth defects and miscarriage for the indicated populations are unknown. All pregnancies carry some risk of birth defects, loss, or other adverse outcomes.
What is the recommended duration of not breastfeeding during treatment with OPZELURA?Because of the serious adverse findings in adults, including risks of serious infections, thrombocytopenia, anemia, and neutropenia, advise women not to breastfeed during treatment with OPZELURA and for approximately four weeks after the last dose (approximately 5-6 elimination half-lives).
What is the safety and effectiveness of OPZELURA in pediatric patients?The safety and effectiveness of OPZELURA for the topical treatment of mild-to-moderate atopic dermatitis have been established in pediatric patients aged 12 to 17 years of age. Use of OPZELURA in this age group is supported by evidence from clinical trials. The safety and effectiveness of OPZELURA in pediatric patients younger than 12 years of age with atopic dermatitis have not been established. The safety and effectiveness of OPZELURA for the topical treatment of nonsegmental vitiligo have been established in pediatric patients aged 12 to 17 years of age. Use of OPZELURA in this age group is supported by evidence from clinical trials. The safety and effectiveness of OPZELURA in pediatric patients younger than 12 years of age with nonsegmental vitiligo have not been established. Oral administration of ruxolitinib to juvenile rats resulted in effects on growth and bone measures.
Is there a difference in safety and effectiveness of OPZELURA between geriatric and younger patients?No clinically meaningful differences in safety or effectiveness were observed between subjects less than 65 years and subjects 65 years and older.
FAQ Data Source